SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: Pseudo Biologist who wrote (1248)6/25/2000 3:18:00 PM
From: Miljenko Zuanic  Read Replies (1) | Respond to of 52153
 
PB,

Isn't true that MEDX diversified their pipeline (old mAbs) by forming subsidiaries and different collaboration type. This indicate that their plan is to spin-off old pipeline (without attention to market them on their own) and focus further growth on xenomouse business (generating high potent and fully human mAb for their partners, and maybe for their own account).

Miljenko

PS: I have hard time to follow their business plan. <g>



To: Pseudo Biologist who wrote (1248)6/25/2000 4:10:00 PM
From: aknahow  Read Replies (1) | Respond to of 52153
 
Thanks, you made things a lot clearer. Still wondering how PDLI will be able to met the competition from xenomouse technology.


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News